Predictive accuracy of prenatal ultrasound findings for lower urinary tract obstruction: A systematic review and Bayesian meta-analysis.


Journal

Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540

Informations de publication

Date de publication:
Aug 2021
Historique:
revised: 21 07 2021
received: 08 06 2021
accepted: 22 07 2021
pubmed: 29 7 2021
medline: 17 12 2021
entrez: 28 7 2021
Statut: ppublish

Résumé

Lower urinary tract obstruction (LUTO) is a rare but critical fetal diagnosis. Different ultrasound markers have been reported with varying sensitivity and specificity. The objective of this systematic review and meta-analysis was to identify the diagnostic accuracy of ultrasound markers for LUTO. We performed a systematic literature review of studies reporting on fetuses with hydronephrosis or a prenatally suspected and/or postnatally confirmed diagnosis of LUTO. Bayesian bivariate random effects meta-analytic models were fitted, and we calculated posterior means and 95% credible intervals for the pooled diagnostic odds ratio (DOR). A total of 36,189 studies were identified; 636 studies were available for full text review and a total of 42 studies were included in the Bayesian meta-analysis. Among the ultrasound signs assessed, megacystis (DOR 49.15, [15.28, 177.44]), bilateral hydroureteronephrosis (DOR 41.33, [13.36,164.83]), bladder thickening (DOR 13.73, [1.23, 115.20]), bilateral hydronephrosis (DOR 8.36 [3.17, 21.91]), male sex (DOR 8.08 [3.05, 22.82]), oligo- or anhydramnios (DOR 7.75 [4.23, 14.46]), and urinoma (DOR 7.47 [1.14, 33.18]) were found to be predictive of LUTO (Table 1). The predictive sensitivities and specificities however are low and wide study heterogeneity existed. Classically, LUTO is suspected in the presence of prenatally detected megacystis with a dilated posterior urethra (i.e., the keyhole sign), and bilateral hydroureteronephrosis. However, keyhole sign has been found to have modest diagnostic performance in predicting the presence of LUTO in the literature which we confirmed in our analysis. The surprisingly low specificity may be influenced by several factors, including the degree of obstruction, and the diligence of the sonographer at searching for and documenting it during the scan. As a result, providers should consider this when establishing the differential for a fetus with hydronephrosis as the presence or absence of keyhole sign does not reliably rule in or rule out LUTO. Megacystis, bilateral hydroureteronephrosis and bladder wall thickening are the most accurate predictors of LUTO. Given the significant consequences of a missed LUTO diagnosis, clinicians providing counselling for prenatal hydronephrosis should maintain a low threshold for considering LUTO as part of the differential diagnosis.

Sections du résumé

BACKGROUND BACKGROUND
Lower urinary tract obstruction (LUTO) is a rare but critical fetal diagnosis. Different ultrasound markers have been reported with varying sensitivity and specificity.
AIMS OBJECTIVE
The objective of this systematic review and meta-analysis was to identify the diagnostic accuracy of ultrasound markers for LUTO.
MATERIALS AND METHODS METHODS
We performed a systematic literature review of studies reporting on fetuses with hydronephrosis or a prenatally suspected and/or postnatally confirmed diagnosis of LUTO. Bayesian bivariate random effects meta-analytic models were fitted, and we calculated posterior means and 95% credible intervals for the pooled diagnostic odds ratio (DOR).
RESULTS RESULTS
A total of 36,189 studies were identified; 636 studies were available for full text review and a total of 42 studies were included in the Bayesian meta-analysis. Among the ultrasound signs assessed, megacystis (DOR 49.15, [15.28, 177.44]), bilateral hydroureteronephrosis (DOR 41.33, [13.36,164.83]), bladder thickening (DOR 13.73, [1.23, 115.20]), bilateral hydronephrosis (DOR 8.36 [3.17, 21.91]), male sex (DOR 8.08 [3.05, 22.82]), oligo- or anhydramnios (DOR 7.75 [4.23, 14.46]), and urinoma (DOR 7.47 [1.14, 33.18]) were found to be predictive of LUTO (Table 1). The predictive sensitivities and specificities however are low and wide study heterogeneity existed.
DISCUSSION CONCLUSIONS
Classically, LUTO is suspected in the presence of prenatally detected megacystis with a dilated posterior urethra (i.e., the keyhole sign), and bilateral hydroureteronephrosis. However, keyhole sign has been found to have modest diagnostic performance in predicting the presence of LUTO in the literature which we confirmed in our analysis. The surprisingly low specificity may be influenced by several factors, including the degree of obstruction, and the diligence of the sonographer at searching for and documenting it during the scan. As a result, providers should consider this when establishing the differential for a fetus with hydronephrosis as the presence or absence of keyhole sign does not reliably rule in or rule out LUTO.
CONCLUSIONS CONCLUSIONS
Megacystis, bilateral hydroureteronephrosis and bladder wall thickening are the most accurate predictors of LUTO. Given the significant consequences of a missed LUTO diagnosis, clinicians providing counselling for prenatal hydronephrosis should maintain a low threshold for considering LUTO as part of the differential diagnosis.

Identifiants

pubmed: 34318486
doi: 10.1002/pd.6025
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1039-1048

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

Anumba DO, Scott JE, Plant ND, Robson SC. Diagnosis and outcome of fetal lower urinary tract obstruction in the northern region of England. Prenat Diagn. 2005;25:7-13.
Malin G, Tonks AM, Morris RK, Gardosi J, Kilby M. Congenital lower urinary tract obstruction: a population-based epidemiological study. BJOG. 2012;119:1455-1464.
Ruano R, Dunn T, Braun MC, Angelo JR, Safdar A. Lower urinary tract obstruction: fetal intervention based on prenatal staging. Pediatr Nephrol. 2017;32:1871-1878.
Sananes N, Cruz-Martinez R, Favre R, et al. Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction. Prenat Diagn. 2016;36:297-303.
Ibirogba ER, Haeri S, Ruano R. Fetal lower urinary tract obstruction: what should we tell the prospective parents? Prenat Diagn. 2020;40:661-668.
Morris RK, Malin GL, Quinlan-Jones E, et al. Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. Lancet. 2013;382:1496-1506.
Kaefer M, Peters CA, Retik AB, Benacerraf BB. Increased renal echogenicity: a sonographic sign for differentiating between obstructive and nonobstructive etiologies of in utero bladder distension. J Urol. 1997;158:1026-1029.
Bernardes LS, Aksnes G, Saada J, et al. Keyhole sign: how specific is it for the diagnosis of posterior urethral valves? Ultrasound Obstetrics Gynecol. 2009;34:419-423.
Abbott JF, Levine D, Wapner R. Posterior urethral valves: inaccuracy of prenatal diagnosis. Fetal Diagn Ther. 1998;13:179-183.
Ruano R, Sananes N, Sangi-Haghpeykar H, et al. Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. Ultrasound Obstet Gynecol. 2015;45:452-458.
Morris RK, Malin GL, Khan KS, Kilby M. Systematic review of the effectiveness of antenatal intervention for the treatment of congenital lower urinary tract obstruction. BJOG. 2010;117:382-390.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement; 2021. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000097
McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synthesis Methods. 2021;12:55-61.
Verde PE. Meta-analysis of diagnostic test data: a bivariate Bayesian modeling approach. Statistics Med. 2010;29:3088-3102.
Verde PE. Bamdit: an R package for Bayesian meta-analysis of diagnostic test data. J Stat Softw. 2018;86:1-32.
Arora M, Prasad A, Kulshreshtha R, Baijal A. Significance of third trimester ultrasound in detecting congenital abnormalities of kidney and urinary tract-a prospective study. J Pediatr Urol. 2019;15:334-340.
Avni EF, Rodesch F, Schulman CC. Fetal uropathies: diagnostic pitfalls and management. J Urol. 1985;134:921-924.
Bhadoo D, Bajpai M, Abid A, et al. Study of prognostic significance of antenatal ultrasonography and renin angiotensin system activation in predicting disease severity in posterior urethral valves. J Indian Assoc Pediatr Surg. 2015;20:63-67.
Blane CE, Koff SA, Bowerman RA, Barr M. Nonobstructive fetal hydronephrosis: sonographic recognition and therapeutic implications. Radiology. 1983;147:95-99.
Boopathy Vijayaraghavan S. Sonography of fetal micturition. Ultrasound Obstet Gynecol. 2004;24:659-663.
Broadley P, McHugo J, Morgan I, Whittle MJ, Kilby MD. The 4 year outcome following the demonstration of bilateral renal pelvic dilatation on pre-natal renal ultrasound. Br J Radiol. 1999;72:265-270.
Bronshtein M, Yoffe N, Brandes JM, Blumenfeld Z. First and early second-trimester diagnosis of fetal urinary tract anomalies using transvaginal sonography. Prenat Diagn. 1990;10:653-666.
Çetinkaya PG, Gülhan B, Düzova A, et al. Clinical characteristics of children with congenital anomalies of the kidney and urinary tract and predictive factors of chronic kidney disease. Turk J Pediatr. 2020;62:746-755.
Chitrit Y, Bourdon M, Korb D, et al. Posterior urethral valves and vesicoureteral reflux: can prenatal ultrasonography distinguish between these two conditions in male fetuses? Prenat Diagn. 2016;36:831-837.
Coplen DE, Hare JY, Zderic SA, Canning DA, Snyder HM, Duckett JW. 10-year experience with prenatal intervention for hydronephrosis. J Urol. 1996;156:1142-1145.
Damen-Elias HaM, De Jong TPVM, Stigter RH, Visser GHA, Stoutenbeek PH. Congenital renal tract anomalies: outcome and follow-up of 402 cases detected antenatally between 1986 and 2001. Ultrasound Obstet Gynecol. 2005;25:134-143.
Dremsek PA, Gindl K, Voitl P, et al. Renal pyelectasis in fetuses and neonates: diagnostic value of renal pelvis diameter in pre- and postnatal sonographic screening. AJR Am J Roentgenol. 1997;168:1017-1019.
Favre R, Kohler M, Gasser B, Muller F, Nisand I. Early fetal megacystis between 11 and 15 weeks of gestation. Ultrasound Obstet Gynecol. 1999;14:402-406.
Fievet L, Faure A, Coze S, et al. Fetal megacystis: etiologies, management, and outcome according to the trimester. Urology. 2014;84:185-190.
Fontanella F, Duin L, Adama van Scheltema PN, et al. Fetal megacystis: prediction of spontaneous resolution and outcome. Ultrasound Obstet Gynecol. 2017;50:458-463.
Fontanella F, Duin LK, Adama van Scheltema PN, et al. Prenatal diagnosis of LUTO: improving diagnostic accuracy. Ultrasound Obstet Gynecol. 2018;52:739-743.
Fontanella F, Duin L, Adama van Scheltema PN, et al. Antenatal workup of early megacystis and selection of candidates for fetal therapy. Fetal Diagn Ther. 2019;45:155-161.
Gloor JM, Ogburn PL, Breckle RJ, Morgenstern BZ, Milliner DS. Urinary tract anomalies detected by prenatal ultrasound examination at Mayo Clinic Rochester. Mayo Clin Proc. 1995;70:526-531.
Gorbe E, Verebely T, Silhavy M, et al. Role of prenatal ultrasonography in the diagnosis and management of urinary tract abnormalities. Med Sci Mon Int Med J Exp Clin Res. 1997;3:CR489-CR494.
Gruenewald SM, Crocker EF, Walker AG, Trudinger BJ. Antenatal diagnosis of urinary tract abnormalities: correlation of ultrasound appearance with postnatal diagnosis. Am J Obstet Gynecol. 1984;148:278-283.
Gunn TR, Mora JD, Pease P. Antenatal diagnosis of urinary tract abnormalities by ultrasonography after 28 weeks’ gestation: incidence and outcome. Am J Obstet Gynecol. 1995;172:479-486.
Harrison MR, Filly RA, Parer JT, et al. Management of the fetus with a urinary tract malformation. J Am Med Assoc. 1981;246:635-639.
Harrison MR, Golbus MS, Filly RA, et al. Management of the fetus with congenital hydronephrosis. J Pediatr Surg. 1982;17:728-742.
Hellstrom WJ, Kogan BA, Jeffrey RB, McAninch JW. The natural history of prenatal hydronephrosis with normal amounts of amniotic fluid. J Urol. 1984;132:947-950.
Hobbins JC, Romero R, Grannum P, Berkowitz RL, Cullen M, Mahoney M. Antenatal diagnosis of renal anomalies with ultrasound. I. Obstructive uropathy. Am J Obstet Gynecol. 1984;148:868-877.
Jouannic J-M, Hyett JA, Pandya PP, Gulbis Ba, Rodeck CH, Jauniaux E. Perinatal outcome in fetuses with megacystis in the first half of pregnancy. Prenat Diagn. 2003;23:340-344.
Lam BC, Wong SN, Yeung CY, Tang M, Ghosh A. Outcome and management of babies with prenatal ultrasonographic renal abnormalities. Am J Perinatol. 1993;10:263-268.
Makled AK, Hamed ME-S. Prenatal three-dimensional ultrasonography in diagnosing fetal renal anomalies. Journal of Evidence-Based Women’s Health Journal Society. 2012;2:60-63.
Miranda M, Sbragia L, Melo Filco A, Kohler H, Barini R, Silva J. Prenatal Hydronephrosis. Int Braz J Ural. 2002;28(2):147-153.
Montemarano H, Bulas DI, Rushton HG, Selby D. Bladder distention and pyelectasis in the male fetus: causes, comparisons, and contrasts. J Ultrasound Med. 1998;17:743-749.
Noia G, Masini L, Caruso A, et al. Prenatal diagnosis of congenital uropathies. Fetal Ther 1989;1(4 Suppl):40-51.
Oktar T, Salabaş E, Kalelioğlu İ, et al. Fetal urinoma and prenatal hydronephrosis: how is renal function affected? Turk J Urol. 2013;39:96-100.
Oliveira EA, Diniz JS, Cabral AC, et al. Predictive factors of fetal urethral obstruction: a multivariate analysis. Fetal Diagn Ther. 2000;15:180-186.
Pellegrino M, Visconti D, Catania VD, et al. Prenatal detection of megacystis: not always an adverse prognostic factor. Experience in 25 consecutive cases in a tertiary referral center, with complete neonatal outcome and follow-up. J Pediatr Urol. 2017;13:486.e1-486.e10.
Plevani C, Locatelli A, Paterlini G, et al. Fetal hydronephrosis: natural history and risk factors for postnatal surgery. J Perinat Med. 2014;42:385-391.
Pocock RD, Witcombe JB, Andrews HS, Berry PJ, Frank JD. The outcome of antenatally diagnosed urological abnormalities. Br J Urol. 1985;57:788-792.
Quinlan RW, Cruz AC, Huddleston JF. Sonographic detection of fetal urinary-tract anomalies. Obstet Gynecol. 1986;67:558-565.
Rani R, Cameron A, Munro F. Prenatal diagnosis and management of urethral obstruction. J Obstet Gynaecol Res. 1997;23:59-62.
Reuss A, Wladimiroff JW, Scholtmeijer RJ, Stewart PA, Sauer PJJ, Niermeijer MF. Prenatal evaluation and outcome of fetal obstructive uropathies. Prenat Diagn. 1988;8:93-102.
Robyr R, Benachi A, Daikha-Dahmane F, Martinovich J, Dumez Y, Ville Y. Correlation between ultrasound and anatomical findings in fetuses with lower urinary tract obstruction in the first half of pregnancy. Ultrasound Obstet Gynecol. 2005;25:478-482.
Rosendahl H. Ultrasound screening for fetal urinary tract malformations: a prospective study in general population. Eur J Obstet Gynecol Reprod Biol. 1990;36:27-33.
Roy S, Colmant C, Cordier AG, Sénat MV. Apport des signes d’appel échographiques dans le diagnostic anténatal des valves de l’urètre postérieur : expérience de 3ans à la maternité de l’hôpital Bicêtre. J de Gynécologie Obstétrique Biol de la Reproduction. 2016;45:478-483.
Jung SY, Oh YT, Kim SY. Predict pregnancy outcomes of prenatal megaureter by prenatal ultrasonography. Clin Exp Obstetrics Gynecol. 2018;45:544-548.
Wollenberg A, Neuhaus TJ, Willi UV, Wisser J. Outcome of fetal renal pelvic dilatation diagnosed during the third trimester. Ultrasound Obstet Gynecol. 2005;25:483-488.
Fontanella F, PNA van Scheltema, Duin L, et al. Antenatal staging of congenital lower urinary tract obstruction. Ultrasound Obstetrics Gynecol. 2019;53:520-524.
Erdman L, Skreta M, Rickard M, et al. Predicting obstructive hydronephrosis based on ultrasound alone. In: Martel AL, Abolmaesumi P, Stoyanov D, et al, eds. Medical Image Computing and Computer Assisted Intervention - MICCAI 2020. Springer; 2020:493-503.
Rickard M, Chua M, Kim JK, et al. Evolving trends in peri-operative management of pediatric ureteropelvic junction obstruction: working towards quicker recovery and day surgery pyeloplasty. World J Urol. 2021. https://doi.org/10.1007/s00345-021-03621-9

Auteurs

Daniel T Keefe (DT)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Jin Kyu Kim (JK)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.
Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

Eric Mackay (E)

Cytel Inc, Toronto, Ontario, Canada.

Michael Chua (M)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Tim Van Mieghem (T)

Department of Obstetrics and Gynecology, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.

Priyank Yadav (P)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Marisol Lolas (M)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Joana Dos Santos (JD)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Marta Skreta (M)

Centre for Computational Medicine, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Lauren Erdman (L)

Centre for Computational Medicine, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

John Weaver (J)

Division of Urology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Antoine Selman Fermin (AS)

Division of Urology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Gregory Tasian (G)

Division of Urology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Armando J Lorenzo (AJ)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Mandy Rickard (M)

Division of Urology, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH